Korean J Transplant.  2022 Mar;36(1):15-28. 10.4285/kjt.22.0001.

Laboratory diagnostic testing for cytomegalovirus infection in solid organ transplant patients

• Lee H
• Oh EJ

• KMID: 2527894
• DOI: http://doi.org/10.4285/kjt.22.0001

Abstract

Human cytomegalovirus (CMV) infection, which is one of the most common complications in transplant recipients, increases the risk of graft loss and rejection. Laboratory strategies for diagnosing CMV infection rely on the measurement of viral DNAemia and CMV-specific cell-mediated immunity (CMV-CMI). The CMV quantitative nucleic acid amplification test (QNAT) enabled the spread of preemptive therapy and prompted recommendations for surveillance, diagnosis, and monitoring. Despite the implementation of the World Health Organization international standard for calibration, variability of QNAT persists due to technical issues. CMV immunoglobulin G serology is the standard method for CMV immune screening of transplant candidates and donors. Assays for CMV-CMI play an important role in helping to predict the risk and to develop an individualized CMV management plan. Genotypic testing for resistance is needed when drug-resistant CMV infection is suspected. Here, we review the state of the art of laboratory tests for CMV infection in solid organ transplantation.

Keyword

Transplantation; Cytomegalovirus; Cell-mediated immunity; Serology; Viral load

Reference

1. Raval AD, Kistler KD, Tang Y, Murata Y, Snydman DR. 2021; Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: a systematic literature review of real-world evidence. Transpl Infect Dis. 23:e13483. DOI: 10.1111/tid.13483. PMID: 33012092.

2. Razonable RR, Humar A. 2019; Cytomegalovirus in solid organ transplant recipients: guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 33:e13512. DOI: 10.1111/ctr.13512. PMCID: PMC6635088. PMID: 30817026.

3. Kim MH, Cho MH, Ahn YH, Bae JM, Moon JS, Kang HG. 2021; Concurrent cytomegalovirus enteritis and atypical hemolytic uremic syndrome with gastrointestinal tract involvement: a case report. Korean J Transplant. 35:262–7. DOI: 10.4285/kjt.21.0017.

4. Kaminski H, Fishman JA. 2016; The cell biology of cytomegalovirus: implications for transplantation. Am J Transplant. 16:2254–69. DOI: 10.1111/ajt.13791. PMID: 26991039.

5. Navarro D. 2016; Expanding role of cytomegalovirus as a human pathogen. J Med Virol. 8:1103–12. DOI: 10.1002/jmv.24450. PMID: 26681168.

6. Razonable RR, Humar A. AST Infectious Diseases Community of Practice. 2013; Cytomegalovirus in solid organ transplantation. Am J Transplant. 13 Suppl 4:93–106. DOI: 10.1111/ajt.12103. PMID: 23465003.

7. Zuhair M, Smit GS, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al. 2019; Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 29:e2034. DOI: 10.1002/rmv.2034. PMID: 30706584.

8. Choi SR, Kim KR, Kim DS, Kang JM, Kim SJ, Kim JM, et al. 2018; Changes in cytomegalovirus seroprevalence in Korea for 21 years: a single center study. Pediatr Infect Vaccine. 25:123–31. DOI: 10.14776/piv.2018.25.e8.

9. La Y, Kwon DE, Yoo SG, Lee KH, Han SH, Song YG. 2019; Human cytomegalovirus seroprevalence and titres in solid organ transplant recipients and transplant donors in Seoul, South Korea. BMC Infect Dis. 19:948. DOI: 10.1186/s12879-019-4607-x. PMID: 31703564. PMCID: PMC6842252.

10. Munoz-Price LS, Slifkin M, Ruthazer R, Poutsiaka DD, Hadley S, Freeman R, et al. 2004; The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis. 39:1293–9. DOI: 10.1086/425002. PMID: 15494905.

11. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, et al. 1997; The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med. 103:106–13. DOI: 10.1016/S0002-9343(97)80021-6. PMID: 9274893.

12. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. 1995; Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 20:1346–53. DOI: 10.1093/clinids/20.5.1346. PMID: 7620022.

13. Park WY, Kim Y, Paek JH, Jin K, Park SB, Han S. 2020; Effectiveness of valacyclovir prophylaxis against the occurrence of cytomegalovirus infection in kidney transplant recipients. Korean J Transplant. 34:15–23.

14. Helanterä I, Lautenschlager I, Koskinen P. 2011; The risk of cytomegalovirus recurrence after kidney transplantation. Transpl Int. 24:1170–8. DOI: 10.1111/j.1432-2277.2011.01321.x. PMID: 21902725.

15. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. 2008; Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 8:975–83. DOI: 10.1111/j.1600-6143.2007.02133.x. PMID: 18261177.

16. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, et al. 2008; Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 46:840–6. DOI: 10.1086/528718. PMID: 18260785.

17. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, et al. 2012; Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 93:61–8. DOI: 10.1097/TP.0b013e318238dab3. PMID: 22094954.

18. Zamora MR. 2002; Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant. 21:841–9. DOI: 10.1016/S1053-2498(02)00435-7. PMID: 12163083.

19. Potena L, Valantine HA. 2007; Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis. 20:425–31. DOI: 10.1097/QCO.0b013e328259c33b. PMID: 17609604.

20. Valantine H. 2004; Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant. 23(5 Suppl):S187–93. DOI: 10.1016/j.healun.2004.03.009. PMID: 15093804.

21. Beam E, Lesnick T, Kremers W, Kennedy CC, Razonable RR. 2016; Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis. Clin Transplant. 30:270–8. DOI: 10.1111/ctr.12686. PMID: 26701733.

22. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. 2017; Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 64:87–91. DOI: 10.1093/cid/ciw668. PMID: 27682069.

23. Hakimi Z, Aballéa S, Ferchichi S, Scharn M, Odeyemi IA, Toumi M, et al. 2017; Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting. Transpl Infect Dis. 19:e12732. DOI: 10.1111/tid.12732. PMID: 28599091.

24. Han SH, Yoo SG, Do Han K, La Y, Kwon DE, Lee KH. 2021; The incidence and effect of cytomegalovirus disease on mortality in transplant recipients and general population: real-world nationwide cohort data. Int J Med Sci. 18:3333–41. DOI: 10.7150/ijms.62621. PMID: 34400903. PMCID: PMC8364452.

25. Razonable RR, Paya CV, Smith TF. 2002; Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol. 40:746–52. DOI: 10.1128/JCM.40.3.746-752.2002. PMID: 11880387. PMCID: PMC120290.

26. Razonable RR, Inoue N, Pinninti SG, Boppana SB, Lazzarotto T, Gabrielli L, et al. 2020; Clinical diagnostic testing for human cytomegalovirus infections. J Infect Dis. 221(Suppl 1):S74–85. DOI: 10.1093/infdis/jiz601. PMID: 32134488. PMCID: PMC7057790.

27. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. 2018; The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 102:900–31. DOI: 10.1097/TP.0000000000002191. PMID: 29596116.

28. Razonable RR, Hayden RT. 2013; Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 26:703–27. DOI: 10.1128/CMR.00015-13. PMID: 24092851. PMCID: PMC3811235.

29. Hirsch HH, Lautenschlager I, Pinsky BA, Cardeñoso L, Aslam S, Cobb B, et al. 2013; An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis. 56:367–73. DOI: 10.1093/cid/cis900. PMID: 23097587. PMCID: PMC3540041.

30. Food and Drug Administration (FDA). 2021. Nucleic acid based tests [Internet]. FDA;Silver Spring, MD: Available from: https://www.fda.gov/medical-devices/vitro-diagnostics/nucleic-acid-based-tests. cited 2021 Dec 16.

31. Beam E, Germer JJ, Lahr B, Yao JD, Limper AH, Binnicker MJ, et al. 2018; Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of immunocompromised patients with CMV pneumonia. Clin Transplant. 32:e13149. DOI: 10.1111/ctr.13149. PMID: 29112278.

32. Boeckh M, Stevens-Ayers T, Travi G, Huang ML, Cheng GS, Xie H, et al. 2017; Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia. J Infect Dis. 215:1514–22. DOI: 10.1093/infdis/jix048. PMID: 28181657. PMCID: PMC5461426.

33. Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, et al. 2019; Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 68:1420–6. DOI: 10.1093/cid/ciy696. PMID: 30137245. PMCID: PMC7348585.

34. Fryer JF, Heath AB, Minor PD. Collaborative Study Group. 2016; A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. Biologicals. 44:242–51. DOI: 10.1016/j.biologicals.2016.04.005. PMID: 27179913.

35. Sidoti F, Piralla A, Costa C, Scarasciulli ML, Calvario A, Conaldi PG, et al. 2019; Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load. Diagn Microbiol Infect Dis. 95:152–8. DOI: 10.1016/j.diagmicrobio.2019.05.012. PMID: 31204110.

36. Preiksaitis JK, Hayden RT, Tong Y, Pang XL, Fryer JF, Heath AB, et al. 2016; Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 63:583–9. DOI: 10.1093/cid/ciw370. PMID: 27307504.

37. Naegele K, Lautenschlager I, Gosert R, Loginov R, Bir K, Helanterä I, et al. 2018; Cytomegalovirus sequence variability, amplicon length, and DNase-sensitive non-encapsidated genomes are obstacles to standardization and commutability of plasma viral load results. J Clin Virol. 104:39–47. DOI: 10.1016/j.jcv.2018.04.013. PMID: 29727833.

38. Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. 2019; Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 19:e260–72. DOI: 10.1016/S1473-3099(19)30107-0. PMID: 31153807.

39. Grossi PA, Baldanti F, Andreoni M, Perno CF. 2020; CMV infection management in transplant patients in Italy. J Clin Virol. 123:104211. DOI: 10.1016/j.jcv.2019.104211. PMID: 31879243.

40. Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T, et al. 2018; Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis. Clin Infect Dis. 66:617–31. DOI: 10.1093/cid/cix793. PMID: 29020339.

41. Hayden RT, Gu Z, Sam SS, Sun Y, Tang L, Pounds S, et al. 2016; Comparative performance of reagents and platforms for quantitation of cytomegalovirus DNA by digital PCR. J Clin Microbiol. 54:2602–8. DOI: 10.1128/JCM.01474-16. PMID: 27535685. PMCID: PMC5035403.

42. Sedlak RH, Kuypers J, Jerome KR. 2014; A multiplexed droplet digital PCR assay performs better than qPCR on inhibition prone samples. Diagn Microbiol Infect Dis. 80:285–6. DOI: 10.1016/j.diagmicrobio.2014.09.004. PMID: 25277746.

43. Sedlak RH, Cook L, Cheng A, Magaret A, Jerome KR. 2014; Clinical utility of droplet digital PCR for human cytomegalovirus. J Clin Microbiol. 52:2844–8. DOI: 10.1128/JCM.00803-14. PMID: 24871214. PMCID: PMC4136144.

44. Limaye AP, Babu TM, Boeckh M. 2020; Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation. Clin Microbiol Rev. 34:e00043–19. DOI: 10.1128/CMR.00043-19. PMID: 33115722. PMCID: PMC7920732.

45. Limaye AP, Santo Hayes TK, Huang ML, Magaret A, Boeckh M, Jerome KR. 2013; Quantitation of cytomegalovirus DNA load in dried blood spots correlates well with plasma viral load. J Clin Microbiol. 51:2360–4. DOI: 10.1128/JCM.00316-13. PMID: 23678066. PMCID: PMC3697661.

46. Kwon S, Jung BK, Ko SY, Lee CK, Cho Y. 2015; Comparison of quantitation of cytomegalovirus DNA by real-time PCR in whole blood with the cytomegalovirus antigenemia assay. Ann Lab Med. 35:99–104. DOI: 10.3343/alm.2015.35.1.99. PMID: 25553288. PMCID: PMC4272973.

47. Prakash K, Chandorkar A, Saharia KK. 2021; Utility of CMV-specific immune monitoring for the management of CMV in solid organ transplant recipients: a clinical update. Diagnostics (Basel). 11:875. DOI: 10.3390/diagnostics11050875. PMID: 34068377. PMCID: PMC8153332.

48. Kirisri S, Vongsakulyanon A, Kantachuvesiri S, Razonable RR, Bruminhent J. 2021; Predictors of CMV infection in CMV-seropositive kidney transplant recipients: impact of pretransplant CMV-specific humoral immunity. Open Forum Infect Dis. 8:ofab199. DOI: 10.1093/ofid/ofab199. PMID: 34113686. PMCID: PMC8186243.

49. Kumar D, Chin-Hong P, Kayler L, Wojciechowski D, Limaye AP, Osama Gaber A, et al. 2019; A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. Am J Transplant. 19:2505–16. DOI: 10.1111/ajt.15315. PMID: 30768834.

50. Jarque M, Crespo E, Melilli E, Gutiérrez A, Moreso F, Guirado L, et al. 2020; Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: a prospective, interventional, multicenter clinical trial. Clin Infect Dis. 71:2375–85. DOI: 10.1093/cid/ciz1209. PMID: 32076718.

51. Costa C, Balloco C, Sidoti F, Mantovani S, Rittà M, Piceghello A, et al. 2014; Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients. J Clin Virol. 61:523–8. DOI: 10.1016/j.jcv.2014.09.015. PMID: 25453571.

52. Rittà M, Costa C, Sidoti F, Ballocco C, Ranghino A, Messina M, et al. 2015; Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients. New Microbiol. 38:329–35. PMID: 26147141.

53. Kim SH, Lee HJ, Kim SM, Jung JH, Shin S, Kim YH, et al. 2015; Diagnostic usefulness of cytomegalovirus (CMV)-specific T cell immunity in predicting CMV infection after kidney transplantation: a pilot proof-of-concept study. Infect Chemother. 47:105–10. DOI: 10.3947/ic.2015.47.2.105. PMID: 26157588. PMCID: PMC4495268.

54. Lee H, Park KH, Ryu JH, Choi AR, Yu JH, Lim J, et al. 2017; Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients. PLoS One. 12:e0189488. DOI: 10.1371/journal.pone.0189488. PMID: 29232714. PMCID: PMC5726762.

55. Schachtner T, Stein M, Reinke P. 2017; CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor. Transplantation. 101:e315–25. DOI: 10.1097/TP.0000000000001825. PMID: 28594749.

56. De Gracia-Guindo MD, Ruiz-Fuentes MD, Galindo-Sacristán P, Osorio-Moratalla JM, Ruiz-Fuentes N, Rodriguez Granger J, et al. 2018; Cytomegalovirus infection monitoring based on interferon gamma release assay in kidney transplantation. Transplant Proc. 50:578–80. DOI: 10.1016/j.transproceed.2017.09.052. PMID: 29579857.

57. Gliga S, Korth J, Krawczyk A, Wilde B, Horn PA, Witzke O, et al. 2018; T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. J Clin Virol. 105:91–6. DOI: 10.1016/j.jcv.2018.06.009. PMID: 29936407.

58. Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, et al. 2018; Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection. J Clin Microbiol. 56:e01040–17. DOI: 10.1128/JCM.01040-17. PMID: 29305542. PMCID: PMC5869821.

59. Sood S, Haifer C, Yu L, Pavlovic J, Gow PJ, Jones RM, et al. 2018; Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation. Transpl Infect Dis. 20:e12934. DOI: 10.1111/tid.12934. PMID: 29809312.

60. Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, et al. 2018; Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients. BMC Infect Dis. 18:179. DOI: 10.1186/s12879-018-3075-z. PMID: 29661141. PMCID: PMC5902940.

61. Páez-Vega A, Poyato A, Rodriguez-Benot A, Guirado L, Fortún J, Len O, et al. 2018; Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response. Antiviral Res. 155:97–105. DOI: 10.1016/j.antiviral.2018.05.006. PMID: 29782877.

62. Thompson G, Boan P, Baumwol J, Chakera A, MacQuillan G, Swaminathan S, et al. 2018; Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia. Pathology. 50:554–61. DOI: 10.1016/j.pathol.2018.04.002. PMID: 29945729.

63. Westall GP, Cristiano Y, Levvey BJ, Whitford H, Paraskeva MA, Paul E, et al. 2019; A randomized study of Quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation. Transplantation. 103:1005–13. DOI: 10.1097/TP.0000000000002454. PMID: 30247316.

64. Kumar D, Mian M, Singer L, Humar A. 2017; An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 17:2468–73. DOI: 10.1111/ajt.14347. PMID: 28500691.

65. Rezahosseini O, Møller DL, Knudsen AD, Sørensen SS, Perch M, Gustafsson F, et al. 2020; Use of T cell mediated immune functional assays for adjustment of immunosuppressive or anti-infective agents in solid organ transplant recipients: a systematic review. Front Immunol. 11:567715. DOI: 10.3389/fimmu.2020.567715. PMID: 33178194. PMCID: PMC7593245.

66. Rogers R, Saharia K, Chandorkar A, Weiss ZF, Vieira K, Koo S, et al. 2020; Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events. BMC Infect Dis. 20:58. DOI: 10.1186/s12879-020-4787-4. PMID: 31952516. PMCID: PMC6969482.

67. Jorgenson MR, Hillis MI, Saddler CM, Smith JA, Parajuli S, Mandelbrot DA. 2020; Prediction of cytomegalovirus infection: a single-center experience utilizing a newly available cell-mediated immunity assay by flow cytometry, a risk factor screening tool, and serologically demonstrated immunity. Transpl Infect Dis. 22:e13311. DOI: 10.1111/tid.13311. PMID: 32386076.

68. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, et al. 2007; Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis. 9:165–70. DOI: 10.1111/j.1399-3062.2006.00199.x. PMID: 17462006.

69. Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, et al. 2013; Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol. 51:2501–7. DOI: 10.1128/JCM.00563-13. PMID: 23678073. PMCID: PMC3719636.

70. Cantisán S, Lara R, Montejo M, Redel J, Rodríguez-Benot A, Gutiérrez-Aroca J, et al. 2013; Pretransplant interferon-γsecretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 13:738–45. DOI: 10.1111/ajt.12049. PMID: 23311355.

71. Valle-Arroyo J, Aguado R, Páez-Vega A, Pérez AB, González R, Fornés G, et al. 2020; Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact. Sci Rep. 10:7194. DOI: 10.1038/s41598-020-64133-x. PMID: 32346028. PMCID: PMC7188901.

72. Jackson SE, Sedikides GX, Mason GM, Okecha G, Wills MR. 2017; Human cytomegalovirus (HCMV)-specific CD4 + T cells are polyfunctional and can respond to HCMV-infected dendritic cells in vitro. J Virol. 91:e02128–16. DOI: 10.1128/JVI.02128-16. PMID: 28053099. PMCID: PMC5331818.

73. Tey SK, Kennedy GA, Cromer D, Davenport MP, Walker S, Jones LI, et al. 2013; Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One. 8:e74744. DOI: 10.1371/journal.pone.0074744. PMID: 24146744. PMCID: PMC3795724.

74. Yong MK, Cameron PU, Slavin MA, Cheng AC, Morrissey CO, Bergin K, et al. 2017; Low T-cell responses to mitogen stimulation predicts poor survival in recipients of allogeneic hematopoietic stem cell transplantation. Front Immunol. 8:1506. DOI: 10.3389/fimmu.2017.01506. PMID: 29170666. PMCID: PMC5684122.

75. Barabas S, Spindler T, Kiener R, Tonar C, Lugner T, Batzilla J, et al. 2017; An optimized IFN-γELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol. 18:14. DOI: 10.1186/s12865-017-0195-y. PMID: 28270111. PMCID: PMC5339961.

76. Tanguay S, Killion JJ. 1994; Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res. 13:259–63. PMID: 7999925.

77. Yong MK, Lewin SR, Manuel O. 2018; Immune monitoring for CMV in transplantation. Curr Infect Dis Rep. 20:4. DOI: 10.1007/s11908-018-0610-4. PMID: 29542023.

78. Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, et al. 2006; Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant. 6:2356–64. DOI: 10.1111/j.1600-6143.2006.01488.x. PMID: 16889599.

79. Gerna G, Lilleri D, Chiesa A, Zelini P, Furione M, Comolli G, et al. 2011; Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant. 11:2463–71. DOI: 10.1111/j.1600-6143.2011.03636.x. PMID: 21827612.

80. Sester U, Gärtner BC, Wilkens H, Schwaab B, Wössner R, Kindermann I, et al. 2005; Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant. 5:1483–9. DOI: 10.1111/j.1600-6143.2005.00871.x. PMID: 15888058.

81. Fernández-Ruiz M, Giménez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, et al. 2019; Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clin Microbiol Infect. 25:381. DOI: 10.1016/j.cmi.2018.05.010. PMID: 29803844.

82. Lutgen CB, Flebbe-Rehwaldt L, Kleiboeker S, Fausett S, Cordes C, Rodgers J, et al. 2017; T-cell immunity panel measures CMV-specific CD4 and CD8 T-cell responses. Open Forum Infect Dis. 4(Suppl 1):S615. DOI: 10.1093/ofid/ofx163.1620. PMCID: PMC5631537.

83. Sester M, Sester U, Gärtner B, Heine G, Girndt M, Mueller-Lantzsch N, et al. 2001; Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation. 71:1287–94. DOI: 10.1097/00007890-200105150-00018. PMID: 11397964.

84. Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, et al. 2010; Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis. 202:585–94. DOI: 10.1086/654931. PMID: 20594105.

85. San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, et al. 2015; Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients. Transpl Infect Dis. 17:637–46. DOI: 10.1111/tid.12417. PMID: 26134282.

86. Blanco-Lobo P, Cordero E, Martín-Gandul C, Gentil MA, Suárez-Artacho G, Sobrino M, et al. 2016; Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation. J Infect. 72:597–607. DOI: 10.1016/j.jinf.2016.02.008. PMID: 26920791.

87. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, et al. 2009; Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 9:1214–22. DOI: 10.1111/j.1600-6143.2009.02618.x. PMID: 19422346.

88. Navarro D, Fernández-Ruiz M, Aguado JM, Sandonís V, Pérez-Romero P. 2019; Going beyond serology for stratifying the risk of CMV infection in transplant recipients. Rev Med Virol. 29:e2017. DOI: 10.1002/rmv.2017. PMID: 30358016.

89. Donadeu L, Revilla-López E, Jarque M, Crespo E, Torija A, Bravo C, et al. 2021; CMV-specific cell-mediated immunity predicts a high level of CMV replication after prophylaxis withdrawal in lung transplant recipients. J Infect Dis. 224:526–31. DOI: 10.1093/infdis/jiaa727. PMID: 33245359.

90. Altaf M, Lineburg KE, Crooks P, Rehan S, Matthews KK, Neller MA, et al. 2021; Pretransplant cytomegalovirus-specific cellular immunity and risk of viral reactivation following lung transplantation: a prospective cohort study. J Infect Dis. 224:312–7. DOI: 10.1093/infdis/jiaa750. PMID: 33274385.

91. Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, et al. 2020; Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 323:1378–87. DOI: 10.1001/jama.2020.3138. PMID: 32286644. PMCID: PMC7157180.

92. Sahoo MK, Lefterova MI, Yamamoto F, Waggoner JJ, Chou S, Holmes SP, et al. 2013; Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol. 51:3700–10. DOI: 10.1128/JCM.01605-13. PMID: 23985916. PMCID: PMC3889754.